Regulators And Pharma Lock Horns On Pricing In India
India's drugs price regulator and the pharmaceutical industry appear to be at loggerheads again, after the government indicated that it could consider introducing an "enabling clause" in the existing regulation that would facilitate fixing the prices of around 300 products where market data is not available.
You may also be interested in...
Tensions between India’s apex drug pricing authority and industry appear set to intensify after the regulator flagged up over 600 “suspected” cases of overcharging. The way forward for both sides is probably only through constructive dialogue and a less combative approach. The Pink Sheet delves into the key sticking points around the standoff.
The Bombay High Court has stayed certain controversial price-related orders by India's National Pharmaceutical Pricing Authority (NPPA), including one pertaining to transitioning "non-scheduled" medicines, as the pharmaceutical industry contests multiple regulatory changes in India.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.